| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cancer Research Campaign Laboratories, Department of Cancer Studies, The Medical School, University of Birmingham, Birmingham B15 2TJ, U.K.
Epstein—Barr virus (EBV)-positive Burkitt's lymphoma (BL) biopsy cells and early passage BL cell lines have been reported as showing an unusual type of virus-cell interaction; at least two EBV latent proteins appear not to be expressed. Serial passage of such lines is often accompanied by a broadening of virus latent gene expression and a corresponding change in the cell surface/growth phenotype towards that shown by in vitro transformed lymphoblastoid cell lines (LCLs). The sequence of events, both viral and cellular, involved in this transition needs to be defined properly. In the present work, phenotypically distinct cell clones have been derived from early passage cultures of a BL cell line in phenotypic transition, thereby giving access to relatively stable cell populations through which the different EBV-B cell interactions within the parental line can be studied. Clones retaining the original BL biopsy cell phenotype (CD10/CD77-positive, activation antigen/adhesion molecule-negative) expressed the virus-encoded nuclear antigen EBNA 1 but not any of the other known latent proteins, EBNAs 2, 3a, 3b, 3c, -LP and latent membrane protein (LMP). Other clones which had developed an LCL-like phenotype (CD10/CD77-negative, activation antigen/adhesion molecule-positive) now expressed all the above latent proteins and also contained significant numbers of cells in lytic cycle. Phenotypic change occurring within the parental BL cell line itself was initiated in a small subpopulation of cells in which the virus-encoded proteins EBNA 2 and LMP were transiently induced to an unusually high level of expression; this was accompanied by the first detectable changes in cell surface phenotype, namely the increase of cellular adhesion molecules. Some control over EBNA 2/LMP expression then appeared to be re-imposed since the presumed clonal descendents of these cells stably expressed EBNA 2 and LMP at much reduced levels typical of those seen in conventional LCLs.
Received 12 December 1989;
accepted 22 February 1990.
This article has been cited by other articles:
|
|
 |
|
  G. Fejer, A. Koroknai, F. Banati, I. Gyory, D. Salamon, H. Wolf, H. H. Niller, and J. Minarovits Latency type-specific distribution of epigenetic marks at the alternative promoters Cp and Qp of Epstein-Barr virus J. Gen. Virol., June 1, 2008; 89(6): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yoshioka, M. M. Crum, and J. T. Sample Autorepression of Epstein-Barr Virus Nuclear Antigen 1 Expression by Inhibition of Pre-mRNA Processing J. Virol., February 15, 2008; 82(4): 1679 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zou, J. Kawada, L. Pesnicak, and J. I. Cohen Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells J. Virol., September 15, 2007; 81(18): 10029 - 10036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Biasio, J. A. Vrana, P. Zhou, L. Qian, C. K. Bieszczad, K. E. Braley, A. M. Domina, S. J. Weintraub, J. M. Neveu, W. S. Lane, et al. N-terminal Truncation of Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is Associated with Stabilization and Abundant Expression in Tumor Cells J. Biol. Chem., August 17, 2007; 282(33): 23919 - 23936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Garibal, E. Hollville, A. I. Bell, G. L. Kelly, B. Renouf, Y. Kawaguchi, A. B. Rickinson, and J. Wiels Truncated Form of the Epstein-Barr Virus Protein EBNA-LP Protects against Caspase-Dependent Apoptosis by Inhibiting Protein Phosphatase 2A J. Virol., July 15, 2007; 81(14): 7598 - 7607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Bell, K. Groves, G. L. Kelly, D. Croom-Carter, E. Hui, A. T. C. Chan, and A. B. Rickinson Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J. Gen. Virol., October 1, 2006; 87(Pt 10): 2885 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Pegman, S. M. Smith, B. N. D'Souza, S. T. Loughran, S. Maier, B. Kempkes, P. A. Cahill, M. J. Simmons, C. Gelinas, and D. Walls Epstein-Barr Virus Nuclear Antigen 2 trans-Activates the Cellular Antiapoptotic bfl-1 Gene by a CBF1/RBPJ{kappa}-Dependent Pathway. J. Virol., August 1, 2006; 80(16): 8133 - 8144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Kis, M. Takahara, N. Nagy, G. Klein, and E. Klein IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines Blood, April 1, 2006; 107(7): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Garcia, J.-F. Garcia, L. Maestre, E. Lucas, L. Sanchez-Verde, S. Romero-Chala, M.-A. Piris, and G. Roncador Genetic Immunization: A New Monoclonal Antibody for the Detection of BCL-6 Protein in Paraffin Sections J. Histochem. Cytochem., January 1, 2006; 54(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Ogden, J. D. Pound, B. K. Batth, S. Owens, I. Johannessen, K. Wood, and C. D. Gregory Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt's Lymphoma J. Immunol., March 1, 2005; 174(5): 3015 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Devitt, K. G. Parker, C. A. Ogden, C. Oldreive, M. F. Clay, L. A. Melville, C. O. Bellamy, A. Lacy-Hulbert, S. C. Gangloff, S. M. Goyert, et al. Persistence of apoptotic cells without autoimmune disease or inflammation in CD14-/- mice J. Cell Biol., December 20, 2004; 167(6): 1161 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Katano, L. Pesnicak, and J. I. Cohen Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas PNAS, April 6, 2004; 101(14): 4960 - 4965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yue, M. G. Davenport, J. Shackelford, and J. S. Pagano Mitosis-Specific Hyperphosphorylation of Epstein-Barr Virus Nuclear Antigen 2 Suppresses Its Function J. Virol., April 1, 2004; 78(7): 3542 - 3552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Thorley-Lawson and A. Gross Persistence of the Epstein-Barr Virus and the Origins of Associated Lymphomas N. Engl. J. Med., March 25, 2004; 350(13): 1328 - 1337. [Full Text] [PDF]
|
|
|
|
|
|
B. N. D'Souza, L. C. Edelstein, P. M. Pegman, S. M. Smith, S. T. Loughran, A. Clarke, A. Mehl, M. Rowe, C. Gelinas, and D. Walls Nuclear Factor {kappa}B-Dependent Activation of the Antiapoptotic bfl-1 Gene by the Epstein-Barr Virus Latent Membrane Protein 1 and Activated CD40 Receptor J. Virol., February 15, 2004; 78(4): 1800 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Iwakiri and K. Takada Phosphatidylinositol 3-Kinase Is a Determinant of Responsiveness to B Cell Antigen Receptor-Mediated Epstein-Barr Virus Activation J. Immunol., February 1, 2004; 172(3): 1561 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hochberg, J. M. Middeldorp, M. Catalina, J. L. Sullivan, K. Luzuriaga, and D. A. Thorley-Lawson Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo PNAS, January 6, 2004; 101(1): 239 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Serafeim, M. J. Holder, G. Grafton, A. Chamba, M. T. Drayson, Q. T. Luong, C. M. Bunce, C. D. Gregory, N. M. Barnes, and J. Gordon Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells Blood, April 15, 2003; 101(8): 3212 - 3219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Richardson, C. Fielding, M. Rowe, and P. Brennan Epstein-Barr Virus Regulates STAT1 through Latent Membrane Protein 1 J. Virol., April 1, 2003; 77(7): 4439 - 4443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Challa, A. G. Eliopoulos, M. J. Holder, A. S. Burguete, J. D. Pound, A. Chamba, G. Grafton, R. J. Armitage, C. D. Gregory, H. Martinez-Valdez, et al. Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells Blood, May 1, 2002; 99(9): 3411 - 3418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Staege, S. P. Lee, T. Frisan, J. Mautner, S. Scholz, A. Pajic, A. B. Rickinson, M. G. Masucci, A. Polack, and G. W. Bornkamm MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells PNAS, April 2, 2002; 99(7): 4550 - 4555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Serafeim, G. Grafton, A. Chamba, C. D. Gregory, R. D. Blakely, N. G. Bowery, N. M. Barnes, and J. Gordon 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors Blood, April 1, 2002; 99(7): 2545 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Marcato, G. Mulvey, and G. D. Armstrong Cloned Shiga Toxin 2 B Subunit Induces Apoptosis in Ramos Burkitt's Lymphoma B Cells Infect. Immun., March 1, 2002; 70(3): 1279 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Adler, E. Schaadt, B. Kempkes, U. Zimber-Strobl, B. Baier, and G. W. Bornkamm Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1 PNAS, December 13, 2001; (2001) 221439999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maruo, A. Nanbo, and K. Takada Replacement of the Epstein-Barr Virus Plasmid with the EBER Plasmid in Burkitt's Lymphoma Cells J. Virol., October 15, 2001; 75(20): 9977 - 9982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Hicks, S. Balesaria, C. Medina-Palazon, M. J. Pandya, D. N. Woolfson, and A. J. Sinclair Biophysical Analysis of Natural Variants of the Multimerization Region of Epstein-Barr Virus Lytic-Switch Protein BZLF1 J. Virol., June 1, 2001; 75(11): 5381 - 5384. [Abstract] [Full Text]
|
|
|
|
|
|
D. Salamon, M. Takacs, D. Ujvari, J. Uhlig, H. Wolf, J. Minarovits, and H. H. Niller Protein-DNA Binding and CpG Methylation at Nucleotide Resolution of Latency-Associated Promoters Qp, Cp, and LMP1p of Epstein-Barr Virus J. Virol., March 15, 2001; 75(6): 2584 - 2596. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Tierney, H. E. Kirby, J. K. Nagra, J. Desmond, A. I. Bell, and A. B. Rickinson Methylation of Transcription Factor Binding Sites in the Epstein-Barr Virus Latent Cycle Promoter Wp Coincides with Promoter Down-Regulation during Virus-Induced B-Cell Transformation J. Virol., November 15, 2000; 74(22): 10468 - 10479. [Abstract] [Full Text]
|
|
|
|
|
|
I. K. Ruf, P. W. Rhyne, C. Yang, J. L. Cleveland, and J. T. Sample Epstein-Barr Virus Small RNAs Potentiate Tumorigenicity of Burkitt Lymphoma Cells Independently of an Effect on Apoptosis J. Virol., November 1, 2000; 74(21): 10223 - 10228. [Abstract] [Full Text]
|
|
|
|
 |
|
 L S Young, C W Dawson, and A G Eliopoulos The expression and function of Epstein-Barr virus encoded latent genes Mol. Pathol., October 1, 2000; 53(5): 238 - 247. [Abstract] [Full Text]
|
|
|
|
|
|
B. D'Souza, M. Rowe, and D. Walls The bfl-1 Gene Is Transcriptionally Upregulated by the Epstein-Barr Virus LMP1, and Its Expression Promotes the Survival of a Burkitt's Lymphoma Cell Line J. Virol., July 15, 2000; 74(14): 6652 - 6658. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Inman and M. J. Allday Resistance to TGF-{beta}1 correlates with a reduction of TGF-{beta} type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines J. Gen. Virol., June 1, 2000; 81(6): 1567 - 1578. [Abstract] [Full Text]
|
|
|
|
|
|
L. Zhang and J. S. Pagano Interferon Regulatory Factor 7 Is Induced by Epstein-Barr Virus Latent Membrane Protein 1 J. Virol., February 1, 2000; 74(3): 1061 - 1068. [Abstract] [Full Text]
|
|
|
|
|
|
K. G. Krauer, M. Buck, and T. Sculley Characterization of the transcriptional repressor RBP in Epstein-Barr virus-transformed B cells J. Gen. Virol., December 1, 1999; 80(12): 3217 - 3226. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. B. Harris, C.-C. Chang, M. T. Berton, N. N. Danial, J. Zhang, D. Kuehner, B. H. Ye, M. Kvatyuk, P. P. Pandolfi, G. Cattoretti, et al. Transcriptional Repression of Stat6-Dependent Interleukin-4-Induced Genes by BCL-6: Specific Regulation of Ivarepsilon Transcription and Immunoglobulin E Switching Mol. Cell. Biol., October 1, 1999; 19(10): 7264 - 7275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Szeles, K. I. Falk, S. Imreh, and G. Klein Visualization of Alternative Epstein-Barr Virus Expression Programs by Fluorescent In Situ Hybridization at the Cell Level J. Virol., June 1, 1999; 73(6): 5064 - 5069. [Abstract] [Full Text]
|
|
|
|
|
|
S. Fujiwara, Y. Nitadori, H. Nakamura, T. Nagaishi, and Y. Ono Epstein-Barr Virus (EBV) Nuclear Protein 2-Induced Disruption of EBV Latency in the Burkitt's Lymphoma Cell Line Akata: Analysis by Tetracycline-Regulated Expression J. Virol., June 1, 1999; 73(6): 5214 - 5219. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Bar-Ner, A. Thibault, M. Tsokos, I. T. Magrath, and D. Samid Phenylbutyrate Induces Cell Differentiation and Modulates Epstein-Barr Virus Gene Expression in Burkitt's Lymphoma Cells Clin. Cancer Res., June 1, 1999; 5(6): 1509 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. D. Moffatt, A. Devitt, E. D. Bell, D. L. Simmons, and C. D. Gregory Macrophage Recognition of ICAM-3 on Apoptotic Leukocytes J. Immunol., June 1, 1999; 162(11): 6800 - 6810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang and J. S. Pagano Interferon Regulatory Factor 2 Represses the Epstein-Barr Virus BamHI Q Latency Promoter in Type III Latency Mol. Cell. Biol., April 1, 1999; 19(4): 3216 - 3223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. K. Ruf, A. Moghaddam, F. Wang, and J. Sample Mechanisms That Regulate Epstein-Barr Virus EBNA-1 Gene Transcription during Restricted Latency Are Conserved among Lymphocryptoviruses of Old World Primates J. Virol., March 1, 1999; 73(3): 1980 - 1989. [Abstract] [Full Text]
|
|
|
|
|
|
I. K. Ruf, P. W. Rhyne, H. Yang, C. M. Borza, L. M. Hutt-Fletcher, J. L. Cleveland, and J. T. Sample Epstein-Barr Virus Regulates c-MYC, Apoptosis, and Tumorigenicity in Burkitt Lymphoma Mol. Cell. Biol., March 1, 1999; 19(3): 1651 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Habeshaw, Q. Y. Yao, A. I. Bell, D. Morton, and A. B. Rickinson Epstein-Barr Virus Nuclear Antigen 1 Sequences in Endemic and Sporadic Burkitt's Lymphoma Reflect Virus Strains Prevalent in Different Geographic Areas J. Virol., February 1, 1999; 73(2): 965 - 975. [Abstract] [Full Text]
|
|
|
|
|
|
N. Kienzle, D. B. Young, D. Liaskou, M. Buck, S. Greco, and T. B. Sculley Intron Retention May Regulate Expression of Epstein-Barr Virus Nuclear Antigen 3 Family Genes J. Virol., February 1, 1999; 73(2): 1195 - 1204. [Abstract] [Full Text]
|
|
|
|
|
|
M. P. Baker, A. G. Eliopoulos, L. S. Young, R. J. Armitage, C. D. Gregory, and J. Gordon Prolonged Phenotypic, Functional, and Molecular Change in Group I Burkitt Lymphoma Cells on Short-Term Exposure to CD40 Ligand Blood, October 15, 1998; 92(8): 2830 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Murray, C. M. Constandinou, J. Crocker, L. S. Young, and R. F. Ambinder Analysis of Major Histocompatibility Complex Class I, TAP Expression, and LMP2 Epitope Sequence in Epstein-Barr Virus-Positive Hodgkin's Disease Blood, October 1, 1998; 92(7): 2477 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kienzle, T. B. Sculley, L. Poulsen, M. Buck, S. Cross, N. Raab-Traub, and R. Khanna Identification of a Cytotoxic T-Lymphocyte Response to the Novel BARF0 Protein of Epstein-Barr Virus: a Critical Role for Antigen Expression J. Virol., August 1, 1998; 72(8): 6614 - 6620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Liebowitz Epstein-Barr Virus and a Cellular Signaling Pathway in Lymphomas from Immunosuppressed Patients N. Engl. J. Med., May 14, 1998; 338(20): 1413 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Falk, L. Szekely, A. Aleman, and I. Ernberg Specific Methylation Patterns in Two Control Regions of Epstein-Barr Virus Latency: the LMP-1-Coding Upstream Regulatory Region and an Origin of DNA Replication (oriP) J. Virol., April 1, 1998; 72(4): 2969 - 2974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshizaki, H. Sato, M. Furukawa, and J. S. Pagano The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1 PNAS, March 31, 1998; 95(7): 3621 - 3626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Taga, K. Carlier, Z. Mishal, C. Capoulade, M. Mangeney, Y. Lecluse, D. Coulaud, C. Tetaud, L. L. Pritchard, T. Tursz, et al. Intracellular Signaling Events in CD77-Mediated Apoptosis of Burkitt's Lymphoma Cells Blood, October 1, 1997; 90(7): 2757 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Staege, S. P. Lee, T. Frisan, J. Mautner, S. Scholz, A. Pajic, A. B. Rickinson, M. G. Masucci, A. Polack, and G. W. Bornkamm MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells PNAS, April 2, 2002; 99(7): 4550 - 4555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Adler, E. Schaadt, B. Kempkes, U. Zimber-Strobl, B. Baier, and G. W. Bornkamm Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1 PNAS, January 8, 2002; 99(1): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
